European Journal of Neurology · 2023 · 10 citations · 33 references
MedicineGeriatric MedicineDementiaGeriatricsGerontologyAlzheimer DiseaseCognitive AgingDementia EpidemiologyDementia PrognosisDementia Risk FactorsDiabetes MellitusAge-specific Dementia RatesAlzheimer Disease DementiaAlzheimer Disease EpidemiologyAlzheimer Disease ProgressionComorbidity Effects On PrognosisCox RegressionDementia Survival AnalysisDiabetes Duration
BACKGROUND AND PURPOSE: This study was undertaken to investigate the longitudinal impact of type 2 diabetes mellitus (T2DM) on the prodromal and dementia stages of Alzheimer disease (AD), focusing on diabetes duration and other comorbidities. METHODS: A total of 1395 dementia-free individuals aged 55-90 years with maximum 15-year follow-up data were enrolled from the Alzheimer's Disease Neuroimaging Initiative database. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) of the incidence of prodromal or dementia stages of AD. RESULTS: Longer T2DM duration (≥5 years; multiadjusted HR = 2.19, 95% confidence interval [CI] = 1.05-4.58), but not shorter T2DM duration (<5 years), was associated with a significantly increased risk of incident prodromal AD over a mean follow-up of 4.8 years. APOE ε4 allele (HR = 3.32, 95% CI = 1.41-7.79) and comorbid coronary artery disease (CAD; HR = 3.20, 95% CI = 1.29-7.95) further increased the risk of incident prodromal AD in patients with T2DM. No significant association was observed between T2DM and the risk of progression from prodromal AD to AD dementia. CONCLUSIONS: T2DM, which is characterized by a longer duration, increases the incidence risk of prodromal AD but not AD dementia. APOE ε4 allele and comorbid CAD strengthen the relationship between T2DM and prodromal AD. These findings highlight T2DM characteristics and its comorbidities as predictors for accurate prediction of AD and screening of at-risk populations.
33
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text
Tiia Ngandu, Jenni Lehtisalo, Alina Solomon et al. · The Lancet · 2015 · 3.6K citations
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Ronald C. Petersen, Paul Aisen, Laurel Beckett et al. · Neurology · 2009 · 2.5K citations · Full text
Medicine, Neurology, Neuroscience +17